Results 161 to 170 of about 53,159 (257)

Enhancing immunotherapy efficacy of hepatocellular carcinoma by inhibiting the key antioxidant factor Nrf2. [PDF]

Mol Ther Oncol
Zhu Y, Liu M, Kwok HF, Chen L.
europepmc   +1 more source

Granzyme K: A new frontier in systemic lupus erythematosus

Rheumatology &Autoimmunity, EarlyView.
The role of Granzyme K in the pathogenesis of systemic lupus erythematosus and its clinical translational significance. Abstract Systemic lupus erythematosus (SLE) is a complex autoimmune disorder driven by dysregulated adaptive and innate immunity and aberrant complement activity.
Zhongyu Chen, Yunjing Pu, Peihui Yang, Qinghuan Zhu, Haojun Long, Danqi Deng   +5 more
wiley   +1 more source

Cell-autonomous co-stimulatory function of membrane-bound CD100 promotes activation and differentiation of HBcAg-specific CD8⁺ T cells. [PDF]

Front Immunol
Zhao M, Chen L, Chen Y, Wang L, Yang X, Sutter K, Lu M, Chen J, Zheng X, Yang D, Wang L, Liu J.   +11 more
europepmc   +1 more source

Peptide‐based responsive molecular fluorescent probes for precision oncology

Responsive Materials, EarlyView.
Peptide‐based responsive fluorescent probes have emerged as adaptive functional materials for precision tumor theranostics, combining tumor‐selective recognition, programmable stimulus responsiveness, and modular tunability. They enable high‐contrast imaging, intraoperative guidance, real‐time monitoring, and multimodal applications, while next ...
Xing Wang, Wen Liu, Jiahao Zhang, Wanqi Wang, Zhicheng Jin, Yuqi Tang, Quan Li   +6 more
wiley   +1 more source

Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models. [PDF]

Cancer Immunol Immunother
Ueda A, Murakami R, Ishida K, Hamada K, Ogura J, Kawahara S, Mise Y, Hosoe Y, Sugimoto M, Wakita D, Miyamoto T, Mizuno R, Taki M, Yamanoi K, Yamaguchi K, Hamanishi J, Mandai M.   +16 more
europepmc   +1 more source

Granzyme M [PDF]

, 2020
openaire   +1 more source

Cancer Vaccine Development: Toward Artificial Intelligence‐Assisted Personalized Cell Membrane Nanovaccine

Small, EarlyView.
Cancer nanovaccines have emerged as promising alternatives to conventional cancer vaccines, which have shown limited clinical efficacy. In particular, cell membrane nanoparticle‐based nanovaccines can offer high biocompatibility and immunogenicity while preserving tumor antigens, including antigen repertoires.
Munsik Kim, Ilkoo Noh
wiley   +1 more source

PCSK9-mediated degradation of cell-surface LDL receptors impairs human CD8+ T cell effector functions. [PDF]

iScience
Markovska A, Lommers LF, Bodelón A, Greve P, van Vark-van der Zee LC, Mulder MT, Roeters van Lennep JE, Zelcer N, Schipper HS, Boes M.   +9 more
europepmc   +1 more source

Redox‐responsive dual‐drug nanomedicine integrating cisplatin and trypsin for synergistic reversal of tumor chemoresistance

Smart Molecules, EarlyView.
This study presents a novel glutathione‐activatable prodrug nanomedicine (cRGD‐PEG‐PGlu‐NP (ssTrypsin & CDDP)) that co‐encapsulates cisplatin and a masked protease to combat cisplatin resistance. The dual‐drug system selectively targets resistant tumor cells, enhancing the efficacy of cisplatin while minimizing systemic toxicity.
Xiaolan Yin, Qi Wang, Ming Zhang, Cheng Zhang, Qixian Chen, Haidong Li, Yan Zhao, Yue Wang, Jingyun Wang, Liuwei Zhang, Hongyan Cui   +10 more
wiley   +1 more source

NK cells promote cardiac cell death and regulate myelopoiesis in myocardial infarction. [PDF]

Nat Commun
Cohen R, Duval V, Al-Rifai R, Maryam S, Santos-Zas I, Braik R, Diedisheim M, Jouve C, Nicoletti S, Thietart S, Guyon T, Chetrit L, Kral M, Döring Y, Weber C, Loupy A, Domenge O, Livrozet M, Hulot JS, Sakalli ET, Rizzo G, Saliba AE, Piollet M, Bruneval P, Tedgui A, Taleb S, Hermine O, Wicks I, Silvestre JS, Hayat S, Cochain C, Vivier E, Ait-Oufella H.   +32 more
europepmc   +1 more source